A randomized controlled study of 6% gabapentin topical formulation for chronic kidney disease-associated pruritus.

Background: Novel agents with good safety profiles are needed in the management of chronic kidney disease-associated pruritus (CKD-AP). This study aims to assess the efficacy and safety of topical gabapentin in the treatment of CKD-AP.

Methods: The authors conducted a randomized, double-blind, vehicle-controlled study.